Predictive Oncology Inc.’s (NASDAQ: POAI) AI-Driven Predictive Models Better Inform Clinicians, Researchers; Changing Landscape of Cancer Treatment
POAI subsidiary Helomics announce sequencing of ovarian tumor cases from UPMC Magee collaboration, a critical step in strategic Cancer Quest 2020 initiative Data key to value in $48-billion precision-medicine industry Industry leaders such as POAI realize critical value in patient-specific, data-driven models The field of drug development for cancer treatment involves costly and time-intensive research. As technology plays an ever-increasing role in driving medicine, researchers and clinicians are discovering the significant potential of patient-derived models in matching specific cancer types with their most effective treatments. These models, which harness the patients’ own cancer cells to best determine how to defeat…







